BiO2 Medical, developer of the Angel Catheter prophylactic pulmonary embolism protection device, said it raised $4 million, according to a regulatory filing.
The Angel catheter is designed to provide access to the central venous system and to trap blood clots before they can reach the lungs, according to the San Antonio, Texas-based company.
BiO2 Medical received $4 million of a hoped-for $10 million from 1 unnamed investor, according to an SEC filing.
In January, BiO2 won a nod from the FDA for a 182-patient pivotal trial of the device in patients at high risk for developing pulmonary embolism who can’t take standard drug therapies.
In May, BiO2 said it enrolled 40 patients within the first 3 months of the trial starting, with 13 sites actively enrolling subjects for the single-arm investigation.
BiO2, which reported raising $12 million in 2012, won CE Mark approval in the European Union for the Angel catheter in May of that year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.